Observational studyJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Open access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping.Alzheimer's research & therapy · 2026Article
- A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.Nature medicine · 2026Article
- Dementia in Progressive Supranuclear Palsy: A Narrative Review.Neurology and therapy · 2026Review
- Targeting tau in Alzheimer's Disease: rationale, approach and challenges.Molecular neurodegeneration · 2026Review
- Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Hybrid Tau-PET/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET.European journal of nuclear medicine and molecular imaging · 2026Article
- From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.Frontiers in aging neuroscience · 2026Review
- A Biomarker-Based Classification of Corticobasal Syndrome.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- First-in-human PET neuroimaging of [European journal of nuclear medicine and molecular imaging · 2025Article
- Developing a novel reference region for [European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.Diagnostics (Basel, Switzerland) · 2025Article
- Relationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy.CNS neuroscience & therapeutics · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials.Brain communications · 2025Review
- Diagnosis and Management of Progressive Corticobasal Syndrome.Current treatment options in neurology · 2024Article
- Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies.European journal of nuclear medicine and molecular imaging · 2024Article
- [18F]PI-2620 Tau PET signal across the aging and Alzheimer's disease clinical spectrum.Imaging neuroscience (Cambridge, Mass.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 7 institutions in 2 countries.
Konstantin MesserschmidtDepartment of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany; konstantin.messerschmidt@medizin.uni-leipzig.de.
Henryk BarthelDepartment of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.
Matthias BrendelDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Cordula ScherlachDepartment of Neuroradiology, Leipzig University Medical Center, Leipzig, Germany.
Karl-Titus HoffmannDepartment of Neuroradiology, Leipzig University Medical Center, Leipzig, Germany.
Boris-Stephan RauchmannDepartment of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany.
Michael RullmannDepartment of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.
Kenneth MarekInviCRO LLC, Boston, Massachusetts.
Victor L VillemagneDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jost-Julian RumpfDepartment of Neurology, Leipzig University Medical Center, Leipzig, Germany.
Dorothee SaurDepartment of Neurology, Leipzig University Medical Center, Leipzig, Germany.
Matthias L SchroeterClinic for Cognitive Neurology, Leipzig University Medical Center, Leipzig, Germany.
Andreas SchildanDepartment of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.
Marianne PattDepartment of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.
Leonie BeyerDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Mengmeng SongDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Carla PalleisDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
Sabrina KatzdoblerDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
Urban M FietzekDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
Gesine RespondekDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Maximilian ScheifeleDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Alexander NitschmannDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Christian ZachDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Olivier BarretInviCRO LLC, Boston, Massachusetts.
Jennifer MadoniaInviCRO LLC, Boston, Massachusetts.
David RussellInviCRO LLC, Boston, Massachusetts.
Andrew W StephensLife Molecular Imaging GmbH, Berlin, Germany; and.
Norman KoglinLife Molecular Imaging GmbH, Berlin, Germany; and.
Sigrun RoeberCenter for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Jochen HermsCenter for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Kai BötzelDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
Peter BartensteinDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases, Site Munich, Bonn, Germany.
John P SeibylInviCRO LLC, Boston, Massachusetts.
Günter HöglingerGerman Center for Neurodegenerative Diseases, Site Munich, Bonn, Germany.
Joseph ClassenDepartment of Neurology, Leipzig University Medical Center, Leipzig, Germany.
Osama SabriDepartment of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.
German Imaging Initiative for Tauopathies (GII4T)
Leipzig University · DELMU Klinikum · DELudwig-Maximilians-Universität München · DEInvicro (United States) · USABT Molecular Imaging (United States) · USMedizinische Hochschule Hannover · DEUniversity of Pittsburgh · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy movement disorder that can be imaged by the
Indexed as
Supranuclear Palsy, ProgressiveAtrophyFluorine RadioisotopesHumansMagnetic Resonance ImagingPyridinestau Proteins((18)F)PI-2620Fluorine RadioisotopesPyridinestau Proteins18F-PI-26204R-tauopathymidbrain atrophyprogressive supranuclear palsytau PET
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.